Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.39 |
| ▸ | FNTA | P49354 | 4/20 | 0.31 |
| ▸ | FNTB | P49356 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877878 | 1.00 | OPRL1 (0.39) | OPRL1KCNH2FNTAFNTB | |
| SCHEMBL12975901 | 0.88 | OPRL1 (0.35) | OPRL1KCNH2 | |
| SCHEMBL12975879 | 0.87 | OPRL1 (0.37) | OPRL1KCNH2 | |
| SCHEMBL13000046 | 0.85 | OPRL1 (0.36) | OPRL1KCNH2 | |
| SCHEMBL2880299 | 0.81 | OPRL1 (0.35) | OPRL1KCNH2FNTAFNTB | |
| SCHEMBL2882647 | 0.80 | OPRL1 (0.33) | OPRL1KCNH2 | |
| SCHEMBL2884890 | 0.80 | OPRL1 (0.33) | OPRL1KCNH2 | |
| SCHEMBL2882638 | 0.80 | OPRL1 (0.33) | OPRL1KCNH2 | |
| SCHEMBL2147997 | 0.79 | CYP2D6 (0.37) | — | |
| SCHEMBL12975874 | 0.78 | CYP2C19 (0.39) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885KCNH2 969/4885FNTA 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.